Metabolische Myopathien – Teil I: Störungen des Kohlehydratstoffwechsels

Lernziele

Diese Übersicht über metabolische Myopathien ist in 2 Teile gegliedert. Ziel dieses ersten Teiles ist es, einen kurzen Überblick über Ursache, Klinik, Diagnose und Therapie der wichtigsten metabolischen Myopathien, bedingt durch Störungen des Kohlehydratstoffwechsels, zu geben.

Literatur

• 1 DiMauro S, Garone C, Naini A. Metabolic myopathies.  Curr Rheumatol Rep. 2010;  12 386-393
• 2 Hermans M C, Pinto Y M, Merkies I S et al. Hereditary muscular dystrophies and the heart.  Neuromuscul Disord. 2010;  20 479-492
• 3 Dehnert C, Bärtsch P. Diagnostik metabolischer Myopathien.  Dtsch Z Sportmed. 2005;  56 179-180
• 4 Ørngreen M C, Jeppesen T D, Andersen S T et al. Fat metabolism during exercise in patients with McArdle disease.  Neurology. 2009;  72 718-724
• 5 Das A M, Steuerwald U, Illsinger S. Inborn errors of energy metabolism associated with myopathies.  J Biomed Biotechnol. 2010;  2010 340 849
• 6 Kazemi-Esfarjani P, Skomorowska E, Jensen T D et al. A nonischemic forearm exercise test for McArdle disease.  Ann Neurol. 2002;  52 153-159
• 7 Zilokowska-Graca B, Kania A, Zwolinska G et al. Adult form of Pompe disease.  Pneumonol Alergol Pol. 2008;  76 396-399
• 8 Ploeg A T, Clemens P R, Corzo van der D et al. A randomized study of alglucosidase alfa in late-onset Pompe’s disease.  N Engl J Med. 2010;  362 1396-1406
• 9 Kishnani P S, Goldenberg P C, DeArmey S L et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.  Mol Genet Metab. 2010;  99 26-33
• 10 Mendelsohn N J, Messinger Y H, Rosenberg A S et al. Elimination of antibodies to recombinant enzyme in Pompe’s disease.  N Engl J Med. 2009;  360 194-195
• 11 Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.  EMBO Mol Med. 2009;  1 268-279
• 12 Kotb M A, Abdallah H K, Kotb A. Liver glycogenoses: are they a possible cause of polyneuropathy? A cross-sectional study.  J Trop Pediatr. 2004;  50 196-202
• 13 Mundy H R, Williams J E, Lee P J et al. Reduction in bone mineral density in glycogenosis type III may be due to a mixed muscle and bone deficit.  J Inherit Metab Dis. 2008;  31 418-423
• 14 Endo Y, Horinishi A, Vorgerd M et al. Molecular analysis of the AGL gene: heterogeneity of mutations in patients with glycogen storage disease type III from Germany, Canada, Afghanistan, Iran, and Turkey.  J Hum Genet. 2006;  51 958-963
• 15 Aoyama Y, Ozer I, Demirkol M et al. Molecular features of 23 patients with glycogen storage disease type III in Turkey: a novel mutation p.R 1147G associated with isolated glucosidase deficiency, along with 9 AGL mutations.  J Hum Genet. 2009;  54 681-686
• 16 Dagli A I, Zori R T, McCune H et al. Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet.  J Inherit Metab Dis. 2009;  32 1-4
• 17 Nadaj-Pakleza A A, Vincitorio C M, Laforêt P et al. Permanent muscle weakness in McArdle disease.  Muscle Nerve. 2009;  40 350-357
• 18 Stojkovic T, Vissing J, Petit F et al. Muscle glycogenosis due to phosphoglucomutase 1 deficiency.  N Engl J Med. 2009;  361 425-427
• 19 Kollberg G, Tulinius M, Gilljam T et al. Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0.  N Engl J Med. 2007;  357 1507-1514
• 20 Moslemi A R, Lindberg C, Nilsson J et al. Glycogenin-1 deficiency and inactivated priming of glycogen synthesis.  N Engl J Med. 2010;  362 1203-1210